Cancer Stem Cell News Volume 10.20 | May 26 2021

2021-05-26 | CSCN 10.20

Cancer Stem Cell News by STEMCELL Technologies
Vol. 10.20 – 26 May, 2021

Exosomal S100A4 Derived from Highly Metastatic Hepatocellular Carcinoma Cells Promotes Metastasis by Activating STAT3

Scientists found that exosomal S100 calcium-binding protein A4 (S100A4) could induce the expression of osteopontin, along with other tumor metastasis/stemness-related genes.
[Signal Transduction and Targeted Therapy]

Full Article

How to prioritize and manage your research projects
PUBLICATIONSRanked by the impact factor of the journal

FMR1/circCHAF1A/miR-211-5p/HOXC8 Feedback Loop Regulates Proliferation and Tumorigenesis via MDM2-Dependent p53 Signaling in GSCs

The novel feedback loop among FMR1, circRNA-CHAF1A (circCHAF1A), miR-211-5p, and HOXC8 in glioma stem cells (GSCs) could facilitate the proliferation and tumorigenesis of glioma and GSCs


GABRP Sustains the Stemness of Triple-Negative Breast Cancer Cells through EGFR Signaling

The authors found that the gamma-aminobutyric acid type A receptor π subunit (GABRP), as a membrane protein enriched in triple-negative breast cancer stem cells, interacted with epidermal growth factor receptor (EGFR) and significantly sustained its expression, resulting in stemness maintenance and chemotherapy resistance.
[Cancer Letters]


UPF1 Promotes Chemoresistance to Oxaliplatin through Regulation of TOP2A Activity and Maintenance of Stemness in Colorectal Cancer

UPF1 enhanced chemoresistance to oxaliplatin in colorectal cancer, which may result from regulation of TOP2A activity and maintenance of stemness.
[Cell Death & Disease]

Full Article

RNA-Sequencing of Long-Term Label-Retaining Colon Cancer Stem Cells Identifies Novel Regulators of Quiescence

Using colon cancer patient-derived organoids and xenografts, researchers identified rare long-term label-retaining quiescent CSCs that could re-enter the cell cycle to generate new tumors.

AbstractFull ArticleGraphical Abstract

The Inhibition of ABCB1/MDR1 or ABCG2/BCRP Enables Doxorubicin to Eliminate Liver Cancer Stem Cells

Scientists explored the role of inhibition of MDR1 or ABCG2 in sensitizing liver CSCs to doxorubicin, the most frequently used chemotherapeutic agent in treating liver cancer.
[Scientific Reports]

Full Article

A Novel Synthetic Microtubule Inhibitor Exerts Antiproliferative Effects in Multidrug Resistant Cancer Cells and Cancer Stem Cells

The novel microtubule inhibitor, 5-(N-methylmaleimid-3-yl)-chromone suppressed the growth and sphere-forming activity of CSCs.
[Scientific Reports]

Full Article

DYRK1A Is Required for Maintenance of Cancer Stemness, Contributing to Tumorigenic Potential in Oral/Oropharyngeal Squamous Cell Carcinoma

The authors reported a novel role of DYRK1A in maintaining tumor growth and stemness of oral/oropharyngeal squamous cell carcinoma cells.
[Experimental Cell Research]

Full Article

Genetic Manipulation of Adhesion GPCR CD97/ADGRE5 Modulates Invasion in Patient-Derived Glioma Stem Cells

Researchers examined CD97 function in primary patient-derived glioma stem cells obtained from five glioblastoma tumors, belonging to three major genetic subtypes.
[Journal of Neuro-Oncology]


Webinar: Organoids as Models for Human Disease

Recent Progress on Targeting Leukemia Stem Cells

Scientists summarize the targeted therapy approaches for the removal of leukemic stem cells (LSCs) through surface markers including immune checkpoint molecules, pathways influencing LSC survival, or the survival microenvironment of LSCs.
[Drug Discovery Today]


MicroRNA-1: Diverse Role of a Small Player in Multiple Cancers

Investigators focus on the different antitumorigenic and therapeutic aspects of miR-1, including how it regulates tumor development and associated immunomodulatory functions.
[Seminars in Cell & Developmental Biology]



KAHR Receives Investment from Cancer Focus Fund to Support Phase I/II Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers

KAHR and Cancer Focus Fund, LP announced that Cancer Focus Fund is investing $5 million to finance a clinical trial of KAHR’s lead anti-CD47 candidate, DSP107, in blood cancers.
[KAHR (PR Newswire, LLC)]

Press Release

AbbVie Receives European Commission Approval of VENCLYXTO® (Venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

AbbVie, Inc. announced that the European Commission has approved VENCLYXTO® in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
[AbbVie, Inc.]

Press Release


Origins of Cancer

July 22 – 23, 2021

> See All Events


Postdoctoral Position – Stemness Control in Pluripotent and Cancer Cells

Columbia University Medical Center – New York, New York, United States

Research Associate – Senescence in Cancer

University of Cambridge – Cambridge, England, United Kingdom

Faculty Positions – Immuno-Oncology

Medical College of Wisconsin – Milwaukee, Wisconsin, United States

Research Associate – Cancer Stem Cell Biology

City of Hope – Duarte, California, United States

Postdoctoral Scientist – Non-Classical Mechanisms of Therapy Resistance

Cedars-Sinai – Los Angeles, California, United States

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Cancer Stem Cell News Twitter